Literature DB >> 28250698

Pharmaceutical Approval Update.

Mary Choy.   

Abstract

Insulin degludec/liraglutide (Xultophy 100/3.6) for type-2 diabetes; rucaparib (Rubraca) for the treatment of deleterious BRCA mutation-associated ovarian cancer; and nusinersen (Spinraza) for the treatment of spinal muscular atrophy.

Entities:  

Year:  2017        PMID： 28250698      PMCID： PMC5312631     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  1 in total

1.  Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy.

Authors:  Benjamin Stolte; Andreas Totzeck; Kathrin Kizina; Saskia Bolz; Lena Pietruck; Christoph Mönninghoff; Nika Guberina; Denise Oldenburg; Michael Forsting; Christoph Kleinschnitz; Tim Hagenacker
Journal:  Ther Adv Neurol Disord       Date:  2018-10-05       Impact factor: 6.570
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.